Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-masked, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of KHN939 in the Treatment of Moderate-to-Severe Inactive Thyroid Eye Disease (TED) in China.

NCT07720648 is registered in ClinicalTrials.gov with Beijing Kanghong Biological Medicine Co., Ltd. as lead sponsor.

NCT NCT07720648
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07720648 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-masked, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of KHN939 in the Treatment of Moderate-to-Severe Inactive Thyroid Eye Disease (TED) in China.
Lead sponsor
Beijing Kanghong Biological Medicine Co., Ltd.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
August 31, 2026
Completion date
June 30, 2027
Enrollment
117 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid eye disease